Skip to main content Accessibility help
×
Home
  • Cited by 1
  • Print publication year: 2010
  • Online publication date: August 2011

6 - Management of isolated hypertension in pregnancy

References

1. RobertsJM, PearsonGD, CutlerJA, LindheimerMD, National Heart Lung and Blood Institute. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy. 2003;22(2):109–27.
2. MilneF, RedmanC, WalkerJ, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005;330(7491):576–80.
3. SibaiBM, CaritisSN, ThomE, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993;329(17):1213–18.
4. KnuistM, BonselGJ, ZondervanHA, TreffersPE. Intensification of fetal and maternal surveillance in pregnant women with hypertensive disorders. Int J Gynaecol Obstet 1998;61(2):127–33.
5. HauthJC, EwellMG, LevineRJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000;95(1):24–8.
6. CampbellDM, MacGillivrayI. Preeclampsia in twin pregnancies: incidence and outcome. Hypertens Pregnancy 1999;18(3):197–207.
7. SibaiBM, HauthJ, CaritisS, et al. Hypertensive disorders in twin versus singleton gestations. Am J Obstet Gynecol 2000;182(4):938–42.
8. BartonJR, O'BrienJM, BergauerNK, JacquesDL, SibaiBM. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001;184(5):979–83.
9. SaudanP, BrownMA, BuddleML, JonesM. Does gestational hypertension become pre-eclampsia?Br J Obstet Gynaecol 1998;105(11):1177–84.
10. KoopmansCM, BijlengaD, GroenH, et al. Induction of labor versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009;374(9694):979–88.
11. SibaiBM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102(1):181–92.
12. BuchbinderA, SibaiBM, CaritisS, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002;186(1):66–71.
13. KnutzenVK, DaveyDA. Hypertension in pregnancy and perinatal mortality. S Afr Med J 1977;51(19):675–9.
14. StellaCL, O'BrienJM, ForresterKJ, et al. The coexistence of gestational hypertension and diabetes: influence on pregnancy outcome. Am J Perinatol 2008;25(6):325–9.
15. PijnenborgR, AnthonyJ, DaveyDA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98(7):648–55.
16. BecroftDM, ThompsonJM, MitchellEA. Placental infarcts, intervillous fibrin plaques, and intervillous thrombi: incidences, cooccurrences, and epidemiological associations. Pediatr Dev Pathol 2004;7(1):26–34.
17. KoenigJM, CheginiN. Enhanced expression of Fas-associated proteins in decidual and trophoblastic tissues in pregnancy-induced hypertension. Am J Reprod Immunol 2000;44(6):347–9.
18. NicolaidesKH, FaratianB, SymondsEM. Effect on low implantation of the placenta on maternal blood pressure and placental function. Br J Obstet Gynaecol 1982;89(10):806–10.
19. AnanthCV, BowesWA, Jr., SavitzDA, LutherER. Relationship between pregnancy-induced hypertension and placenta previa: a population-based study. Am J Obstet Gynecol 1997;177(5):997–1002.
20. NemethI, TalosiG, PappA, BodaD. Xanthine oxidase activation in mild gestational hypertension. Hypertens Pregnancy 2002;21(1):1–11.
21. StrevensH, Wide-SwenssonD, HansenA, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003;110(9):831–6.
22. VillarJ, CarroliG, WojdylaD, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?Am J Obstet Gynecol 2006;194(4):921–31.
23. ZafirovskaKG, MaleskaVT, BogdanovskaSV, et al. Plasma human atrial natriuretic peptide, endothelin-1, aldosterone and plasma-renin activity in pregnancy-induced hypertension. J Hypertens 1999;17(9):1317–22.
24. LeeMI, BottomsSF, SokolRJ, ToddHM. Angiotensin converting enzyme activity in hypertensive pregnancy. J Perinat Med 1987;15(3):258–62.
25. Nalogowska-GlosnickaK, LackaBI, ZychmaMJ, et al. Angiotensin II type 1 receptor gene A1166C polymorphism is associated with the increased risk of pregnancy-induced hypertension. Med Sci Monit 2000;6(3):523–9.
26. MeagherEA, FitzGeraldGA. Disordered eicosanoid formation in pregnancy-induced hypertension. Circulation 1993;88(3):1324–33.
27. RobertsJM, BodnarLM, LainKY, et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension.[see comment]. Hypertension 2005;46(6):1263–9.
28. BergelE, CarroliG, AlthabeF. Ambulatory versus conventional methods for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev 2002;(2):CD001231.
29. BiswasA, ChoolaniMA, AnandakumarC, ArulkumaranS. Ambulatory blood pressure monitoring in pregnancy induced hypertension. Acta Obstet Gynecol Scand 1997;76(9):829–33.
30. MathewsDD, AgarwalV, ShuttleworthTP. The effect of rest and ambulation on plasma urea and urate levels in pregnant women with proteinuric hypertension. Br J Obstet Gynaecol 1980;87(12):1095–8.
31. CrowtherCA, BouwmeesterAM, AshurstHM. Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension?Br J Obstet Gynaecol 1992;99(1):13–17.
32. BartonJR, WitlinAG, Sibai BM. Management of mild preeclampsia. Clin Obstet Gynecol 1999;42(3):455–69.
33. TuffnellDJ, LilfordRJ, BuchanPC, et al. Randomised controlled trial of day care for hypertension in pregnancy. Lancet 1992;339(8787):224–7.
34. DuleyL, Henderson-SmartD, MeherS. Altered dietary salt for preventing preeclampsia, and its complications. Cochrane Database Syst Rev 2005;(4):CD005548.
35. NicholsonJM, KellarLC, KellarGM. The impact of the interaction between increasing gestational age and obstetrical risk on birth outcomes: evidence of a varying optimal time of delivery. J Perinatol 2006;26(7):392–402.
36. MageeLA, von DadelszenP, ChanS, et al. The Control of Hypertension In Pregnancy Study pilot trial. BJOG 2007;114(6):770, e13–20.
37. El GuindyAA, NabhanAF. A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy. J Perinat Med 2008;36(5):413–18.
38. DuleyL, Henderson-SmartDJ. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2002;(4):CD001449.
39. HeazellAEP, MahomoudS, PirieAM. Current knowledge and practice in treatment of severe acute hypertension in pregnancy – an audit of practice in West Midlands obstetric units. J Obstet Gynaecol 2004;24(8):897–8.
40. PicklesCJ, SymondsEM, Broughton PipkinF. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989;96(1):38–43.
41. GalleryED, SaundersDM, HunyorSN, GyoryAZ. Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J 1979;1(6178):1591–4.
42. RubinPC, LowRA, ReidJL. Antihypertensive therapy in pregnancy. Lancet 1983;1(8334):1160.
43. ButtersL, KennedyS, RubinPC. Atenolol in essential hypertension during pregnancy. BMJ 1990;301(6752):587–9.
44. GazzoloD, VisserGH, SantiF, et al. Behavioural development and Doppler velocimetry in relation to perinatal outcome in small for dates fetuses. Early Hum Dev 1995;43(2):185–95.
45. WatermanEJ, MageeLA, LimKI, et al. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy 2004;23(2):155–69.
46. MageeLA, ChamC, WatermanEJ, OhlssonA, von DadelszenP. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327(7421):955–60.
47. ImpeyL. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993;100:959–61.
48. GrossmanE, MesserliFH, GrodzickiT, KoweyP. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?[see comment]. JAMA 1996;276(16):1328–31.
49. MageeLA, SchickB, DonnenfeldAE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996;174(3):823–8.
50. PrevostRR, AklSA, WhybrewWD, SibaiBM. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1992;12(3):174–7.
51. BartonJR, PrevostRR, WilsonDA, WhybrewWD, SibaiBM. Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. Am J Obstet Gynecol 1991;165(4 Pt 1):951–4.
52. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol 1998;105(7):718–22.
53. Royal Pharmaceutical Society of Great Britain. British National Fomulary. London, BMJ and Royal Pharmaceutical Society, 2009.
54. RedmanCW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976;2(7989):753–6.
55. MontanS, AnandakumarC, ArulkumaranS, IngemarssonI, RatnamSS. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol 1993;168(1 Pt 1):152–6.
56. HoulihanDD, DennedyMC, RavikumarN, MorrisonJJ. Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. J Perinat Med 2004;32(4):315–19.
57. CockburnJ, MoarVA, OunstedM, RedmanCW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;1(8273):647–9.
58. JacobsM. Mechanism of action of hydralazine on vascular smooth muscle. Biochem Pharmacol 1984;33(18):2915–19.
59. KnowlesHJ, TianYM, MoleDR, HarrisAL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 2004;95(2):162–9.
60. Paterson-BrownS, RobsonSC, RedfernN, WalkinshawSA, de SwietM. Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia. Br J Obstet Gynaecol 1994;101(5):409–13.
61. CollinsR, ChalmersI, PetoR. Antihypertensive treatment in pregnancy. Br Med J (Clin Res Ed) 1985;291(6502):1129.
62. CarrDB, GavrilaD, BratengD, EasterlingTR. Maternal hemodynamic changes associated with furosemide treatment. Hypertens Pregnancy 2007;26(2):173–8.
63. LaubeGF, KemperMJ, SchubigerG, NeuhausTJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 2007;92(5):F402–3.
64. SerreauR, LutonD, MacherMA, et al. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005;112(6):710–12.